Learn More
Medchemexpress LLC Adagrasib | 2326521-71-3 | >99.9% | 200 MG

Supplier: Medchemexpress LLC HY130149200MG
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. It covalently binds to KRAS G12C at the cysteine at residue 12, locking the protein in its inactive GDP-bound conformation and inhibiting KRAS-dependent signal transduction.
- Potent and orally-available.
- Mutation-selective covalent inhibitor of KRAS G12C.
- Potential antineoplastic activity.
- Inhibits KRAS-dependent signal transduction.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.